Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 2
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD, Skalsky A, McDonald CM. Biggar WD, et al. J Neuromuscul Dis. 2022;9(4):463-476. doi: 10.3233/JND-210776. J Neuromuscul Dis. 2022. PMID: 35723111 Free PMC article. Review.
Both have been used off-label for many years (choice dependent on patient preference, cost, and geographic location) before FDA approval of deflazacort for DMD in 2017. In this review, we compare deflazacort and prednisone/prednisolone in terms of their key pharmaco …
Both have been used off-label for many years (choice dependent on patient preference, cost, and geographic location) before FDA approval of …
Update in Duchenne and Becker muscular dystrophy.
Waldrop MA, Flanigan KM. Waldrop MA, et al. Curr Opin Neurol. 2019 Oct;32(5):722-727. doi: 10.1097/WCO.0000000000000739. Curr Opin Neurol. 2019. PMID: 31343429 Review.
RECENT FINDINGS: Treatment of DMD patients with the corticosteroids prednisone or deflazacort remains the standard of care, and recent data shows that early treatment (as young as 5 months) with a weekend dosing regimen results in measurable improvement in motor outcomes. …
RECENT FINDINGS: Treatment of DMD patients with the corticosteroids prednisone or deflazacort remains the standard of care, and recen …
The Dystrophinopathies.
Thangarajh M. Thangarajh M. Continuum (Minneap Minn). 2019 Dec;25(6):1619-1639. doi: 10.1212/CON.0000000000000791. Continuum (Minneap Minn). 2019. PMID: 31794463 Review.
Advances in Dystrophinopathy Diagnosis and Therapy.
Saad FA, Siciliano G, Angelini C. Saad FA, et al. Biomolecules. 2023 Aug 28;13(9):1319. doi: 10.3390/biom13091319. Biomolecules. 2023. PMID: 37759719 Free PMC article. Review.
Pharmacological therapy for dystrophinopathies comprises glucocorticoids (prednisone, prednisolone, and deflazacort), vamorolone, and ataluren. However, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers are the first-li …
Pharmacological therapy for dystrophinopathies comprises glucocorticoids (prednisone, prednisolone, and deflazacort), vamorolone, and …
Glucocorticoid-Induced Osteoporosis (GIOP).
Jha SS. Jha SS. Indian J Orthop. 2023 Nov 29;57(Suppl 1):181-191. doi: 10.1007/s43465-023-01037-8. eCollection 2023 Dec. Indian J Orthop. 2023. PMID: 38107807 Review.
A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. Bylo M, et al. Ann Pharmacother. 2020 Aug;54(8):788-794. doi: 10.1177/1060028019900500. Epub 2020 Feb 4. Ann Pharmacother. 2020. PMID: 32019318 Review.
Objective: The objective of this article is to review the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, and formulary considerations of deflazacort. Data Sources: A search of MEDLINE and EMBASE (1946 to December 31, 2019) was conducted using …
Objective: The objective of this article is to review the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, and f …
Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL, Cook T, Miller H. Wong BL, et al. J Comp Eff Res. 2022 Aug;11(11):779-786. doi: 10.2217/cer-2022-0055. Epub 2022 Jun 17. J Comp Eff Res. 2022. PMID: 35713895 Free article. Review.
Overall, the researchers found that the participants who took deflazacort were able to walk until a later age before they needed to use a wheelchair, compared with those who took prednisone. ...These results helped the researchers to learn more about the differences betwee …
Overall, the researchers found that the participants who took deflazacort were able to walk until a later age before they needed to u …
Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy.
Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM. Quattrocelli M, et al. J Neuromuscul Dis. 2021;8(1):39-52. doi: 10.3233/JND-200556. J Neuromuscul Dis. 2021. PMID: 33104035 Free PMC article. Review.
Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy. …
Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as predniso …
Duchenne muscular dystrophy: an historical treatment review.
Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH. Werneck LC, et al. Arq Neuropsiquiatr. 2019 Sep 5;77(8):579-589. doi: 10.1590/0004-282X20190088. Arq Neuropsiquiatr. 2019. PMID: 31508685 Free article. Review.
Of all the treatments, the only drugs that are still considered able to modify the course of the disease are the corticosteroids (prednisone/prednisolone/deflazacort). Other drugs (coenzyme Q10 and creatine) have had a little effect in a few functions without adverse react …
Of all the treatments, the only drugs that are still considered able to modify the course of the disease are the corticosteroids (prednisone …
Etanercept treatment for pediatric toxic epidermal necrolysis induced by deflazacort: a case report and literature review.
Jeong MS, Choi YY, Ahn YH, Lee K, Park JS, Suh DI. Jeong MS, et al. Front Immunol. 2024 Jan 25;15:1342898. doi: 10.3389/fimmu.2024.1342898. eCollection 2024. Front Immunol. 2024. PMID: 38333208 Free PMC article. Review.
Herein, we report the case of a 44-month-old boy who developed TEN due to deflazacort as the probable culprit drug and was successfully treated with etanercept. ...Under the diagnosis of Steven Johnson syndrome/TEN, deflazacort was discontinued, and intravenous dexa …
Herein, we report the case of a 44-month-old boy who developed TEN due to deflazacort as the probable culprit drug and was successful …
13 results